CERVIX

Pre-Invasive
AGUS PAP

Fertility-Preserving
1A1 and 1A2 (≤ 2 cm)

RH-Nodes
GOG 92 Sedlis Criteria
GOG 109 Peters Criteria

Locally Advanced
Positive or negative nodes
Positive lymph nodes
Positive lymph nodes

Recurrent/Persistent
Progression s/p chemoRx plus bevacizumab

GOG 237: Comparative analysis of CA-IX, p16, proliferative markers and HPV in the diagnosis of significant cervical lesions in patients with a cytologic diagnosis of atypical glandular cells.

GOG 278: Evaluation of physical function and QoL before and after non-radical surgical therapy (extra-fascial hysterectomy or cone biopsy with pelvic lymphadenectomy)

GOG 263: Phase III randomized – adjuvant RT vs chemoRT in intermediate risk stage I/IIA cervix s/p RH-nodes

GOG 724: Phase III randomized – chemoRT +/- adjuvant chemoRx in high-risk early stage cervix s/p RH-nodes

GOG 274 (OUTBACK): Phase III randomized – primary chemoRT +/- adjuvant chemoRx

GOG 9929: Phase I sequential Ipilimumab after chemoRT for stage IB2/IIA/IIIB/IVA with positive nodes

GOG 3009: A Phase III Trial of ADXS11-001 administered following chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cancer. CDA was signed on 10/26/15

GOG 265: Phase II ADXS11-001 recurrent/persistent squamous or non-squamous cervix Temp closed per GOG

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu